Daiichi Sankyo Co Ltd (D4S.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
As of 08:00AM CEST. Market open.
| Previous close | 27.29 |
| Open | 27.83 |
| Bid | 27.75 x N/A |
| Ask | 28.58 x N/A |
| Day's range | 27.83 - 27.83 |
| 52-week range | 22.35 - 33.74 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
ZacksMerck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
ZacksAstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.
© 2024 Yahoo. All rights reserved.